Chugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a leading Japanese biopharmaceutical company headquartered in Tokyo. Established in 1925, Chugai has grown from a domestic drug manufacturer into a globally recognized research-driven organization. In 2002, Chugai entered into a strategic alliance with Roche, one of the world’s largest biotechnology companies, strengthening its research and development capabilities and expanding its global reach. This partnership has enabled Chugai to leverage advanced technologies and accelerate the development of innovative therapies.
The company’s main business activities center on the discovery, development, manufacturing and marketing of prescription pharmaceuticals, with a particular focus on oncology, bone and joint diseases, renal diseases, and immunology. Among its flagship products are Actemra (tocilizumab), used for rheumatoid arthritis and cytokine release syndrome; Alecensa (alectinib), a targeted therapy for lung cancer; and Hemlibra (emicizumab), a treatment for hemophilia A. Chugai also maintains a robust pipeline of investigational compounds, with ongoing clinical trials in areas such as Alzheimer’s disease, multiple myeloma and metabolic disorders.
While its primary market is Japan, Chugai supports patients around the world through collaborations, licensing agreements and co-marketing arrangements with Roche and other international partners. The company operates research laboratories in Japan and Switzerland, and maintains a presence in North America and Europe through affiliate offices. This global footprint allows Chugai to combine insights from diverse patient populations with cutting-edge scientific expertise.
Under the leadership of President and CEO Osamu Okuda, Chugai continues to emphasize patient-centric innovation and sustainable growth. Its board comprises leaders with expertise in pharmaceutical development, regulatory affairs and global strategy, guiding the company as it pursues ambitious goals in personalized medicine. Through ongoing investment in biotechnology platforms—such as antibody engineering, protein degradation technologies and cell therapy—Chugai aims to bring transformative treatments to patients and reinforce its standing in the international biopharmaceutical community.
